(BYSI) – FDA
-
BeyondSpring (BYSI) Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conference
-
BeyondSpring (BYSI) Presents New Clinical Data in the Chemotherapy-Induced Neutropenia
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to BYSI Stock Lookup